NASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis $1.87 -0.07 (-3.61%) Closing price 04:00 PM EasternExtended Trading$1.87 0.00 (0.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Entera Bio Stock (NASDAQ:ENTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entera Bio alerts:Sign Up Key Stats Today's Range$1.82▼$2.0050-Day Range$1.85▼$2.7252-Week Range$1.30▼$3.35Volume69,550 shsAverage Volume147,397 shsMarket Capitalization$66.92 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Read More… Entera Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreENTX MarketRank™: Entera Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 708th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntera Bio has received no research coverage in the past 90 days.Read more about Entera Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Entera Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.33% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently increased by 59.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.33% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently increased by 59.54%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentEntera Bio has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Entera Bio this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.11% of the stock of Entera Bio is held by institutions.Read more about Entera Bio's insider trading history. Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Stock News HeadlinesEntera Bio to Participate in Upcoming EventsFebruary 24, 2025 | globenewswire.comEntera Bio announces acceptance of EB613 abstracts for WCO-IOF-ESCEOFebruary 19, 2025 | markets.businessinsider.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…March 6, 2025 | Investors Alley (Ad)Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?February 6, 2025 | uk.finance.yahoo.comEntera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 27, 2025 | globenewswire.comEntera Bio Buy Rating: Strong Financials, Strategic Developments, and Promising Pipeline Drive Analyst ConfidenceNovember 12, 2024 | markets.businessinsider.comEntera Bio Highlights Q3 2024 Financials and FDA AnticipationNovember 9, 2024 | markets.businessinsider.comEntera Bio Reports Q3 2024 Financial Results and Provides Business UpdatesNovember 8, 2024 | globenewswire.comSee More Headlines ENTX Stock Analysis - Frequently Asked Questions How have ENTX shares performed this year? Entera Bio's stock was trading at $2.12 at the start of the year. Since then, ENTX shares have decreased by 11.8% and is now trading at $1.87. View the best growth stocks for 2025 here. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) posted its quarterly earnings results on Friday, August, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The company earned $0.06 million during the quarter. When did Entera Bio IPO? Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager. Who are Entera Bio's major shareholders? Top institutional shareholders of Entera Bio include Knoll Capital Management LLC (16.44%), Schonfeld Strategic Advisors LLC (1.77%), Northern Trust Corp (0.59%) and Perigon Wealth Management LLC (0.41%). Insiders that own company stock include Miranda Jayne Toledano, Sean Ellis and Haya Taitel. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and General Electric (GE). Company Calendar Last Earnings8/09/2024Today3/06/2025Next Earnings (Estimated)3/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTX CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+437.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax Margin-9,270.71% Return on Equity-107.24% Return on Assets-92.29% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual Sales$99,000.00 Price / Sales672.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book5.17Miscellaneous Outstanding Shares35,785,000Free Float31,884,000Market Cap$66.56 million OptionableOptionable Beta1.62 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ENTX) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNew Way To Target 2x Trades Every Monday MorningNo. 1 Stock to Buy for THIS MONDAY Heads up: Tim Bohen’s new algorithm just uncovered a dirt-cheap stock th...StocksToTrade | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | Sponsored2025 AI Blueprint: Nvidia’s more important than everAI is Big Tech’s #1 priority in 2025—Amazon, Microsoft, Google, and Meta are pouring a record $320 billion int...Weiss Ratings | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.